World apheresis registry 2003–2007 data

Stegmayr, Bernd; Pták, Jan; Wíkström, Björn; Berlin, Gösta; Axelsson, C. G.; Griskevicius, A.; Centoni, Paolo Emilio; Liumbruno, Giancarlo Maria; Molfettini, Pietra; Audzijoniene, J.; Mokvist, K; Sojka, Birgitta Nilsson; Norda, Rut; Knutson, Folke; Ramlow, Wolfgang; Bláha, M.; Witt, Volker; Evergren, M.; Tomaz, J.

doi:10.1016/j.transci.2008.09.003

Cited by 69 publications

(79 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The World Apheresis Registry data show that 98.3% of centrifugal apheresis procedures are performed with ACD-A alone. 11 Citrate is easy to use and neutralized within 36 min in patients without compromised liver function. 12 The recommended citrate ratio during PTPs with Optia is 12:1 (WB:ACD-A).…”

Section: Discussionmentioning

confidence: 99%

“…Registry data from other cellseparating systems indicated that peripheral venous access was used in 71% of apheresis procedures, central catheter in 21.2%, and AV fistula in 4%. 11 Besides vascular access, the anticoagulant type, replacement fluid, underlying diseases, as well as the type of PTP have a great impact on the appearance of AEs and complications. 2 As citrate exclusively anticoagulates the extracorporeal circuit, citrate-induced AEs occur only in 0.08%-1.2% of the procedures.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Spectra Optia apheresis system: experience with secondary plasma devices

Rummler¹,

Volkholz²,

Steinke³

et al. 2017

IJCTM

View full text Add to dashboard Cite

Abstract:Performing clinical procedures and optimal management of Spectra Optia in combination with secondary plasma devices (SPDs) have not been described in the literature. To contribute to this topic, we examined 300 data log files from patients treated with the Spectra Optia from November 2015 until October 2016. Of these 300 procedures, 149 secondary plasma treatments were conducted in 13 patients (76 immunoadsorption [IA] and 73 lipoprotein apheresis [LA]). Nine patients had IA due to transplantation and autoimmune diseases. Four patients were treated with LA after heart transplantation. Of the procedures, 62% were performed using peripheral venous access, even in patients with a low inlet blood flow. A central catheter was required only in 15% cases, and an arteriovenous fistula in 23% of the procedures. Anticoagulation management differed in both procedures. The LA procedures required a higher amount of citrate as they were performed using only citrate. The IA procedures required less citrate because a mixture of citrate and heparin was used. We did not observe clotting or bleeding, regardless of heparin use. Due to strict calcium management, no patient showed signs of hypocalcemia. Despite our apheresis management, four procedures had to be canceled preliminarily due to patient complications. The targeted substances could be reduced significantly: lipoprotein (a) (Lpa) level by 68% (76%-45%), low-density lipoprotein-cholesterol by 57% (64%-37%), and IgG from 6.6 (1.09-21.0) to 2.61 (0.33-14.7) g/l. The Cobe could be replaced by the Optia system effectively. The Optia has a high plasma extraction efficiency, which allows SPD procedures with peripheral venous access and moderate inlet flow rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Spectra Optia apheresis system: experience with secondary plasma devices

Rummler¹,

Volkholz²,

Steinke³

et al. 2017

IJCTM

View full text Add to dashboard Cite

show abstract

“…[14] The overall mortality rate in PE, neurological and nonneurological indications combined together, is estimated to be 1-3 per 10,000 procedures. [15,16] Globally, neurological disorders constitute the leading indication for PE, followed by hematological, renal and rheumatologic disorders. Hyperviscosity syndrome, cryoglobulinemia, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome and idiopathic thrombocytopenia are some of the leading haematological indications [17,18].…”

Section: Discussionmentioning

confidence: 99%

Theraputic Plasmapheresis in Neurological Disorders, Baghdad/Iraq

Jabar¹

2016

AJIM

View full text Add to dashboard Cite

Abstract:Background: plasma exchange (PE) involves the separation and removal of plasma from corpuscular blood and the replacement of it with various fluids, while plasmapheresis only refers to the removal of plasma. AIM OF STUDY: To study our experience with PE in our 487 patients of different neurological disorders, determined most referring diseases. Materials and Methods: Retrospective study of PE procedures done during a period of 36 months, from January 2013to January 2016 in a neurosciences hospital in Baghdad/Iraq. Data analysis is used SPSS 20. Results: The main indication for PE was CIDP (339 patients; 69.20%). Age of patients ranged from 8-85 (mean = 46.22 years). Up to our knowledge is largeset number of patients used in that period, no mortality found. Conclusion: The analysis of 487 cases of PE done in our department shows that PF is usually well tolerated. Possible adverse reactions mainly relate to vascular access.

show abstract

“…A Canadian Apheresis Registry report on over 144,000 procedures showed adverse events in 12% of procedures (mostly minor), and severe events in only 0.4% of procedures [10]. The World Apheresis Registry reported adverse events in 5.7% of over 12,000 procedures, severe adverse events in only 0.5%, and no deaths [11]. Our own recent study of around 1,200 procedures in the UK reported adverse events in only 1.7%, with no deaths [12].…”

Section: Complicationsmentioning

confidence: 99%

Plasmapheresis in Immunologic Renal Disease

Pusey

Levy²

2012

Blood Purif

View full text Add to dashboard Cite

Plasmapheresis has been used in the management of immunologic renal disease for the last 40 years. The rationale behind this approach is to remove pathogenic immune mediators, such as autoantibodies and immune complexes, from the circulation. There may also be benefit in depleting proinflammatory molecules, such as complement components and coagulation factors. Initial experience was gained in Goodpasture’s disease, in which antiglomerular basement membrane antibodies were known to be pathogenic. More recently, a role for autoantibodies has become clear in small-vessel systemic vasculitis and some cases of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Removal of immune complexes is thought to be important in cryoglobulinemia and systemic lupus erythematosus. Plasmapheresis is used in renal transplantation for the treatment of acute antibody-mediated rejection, and for desensitization of patients with preformed anti-HLA antibodies or those receiving an ABO-incompatible transplant. Although many of the early studies were uncontrolled, there has been an increasing number of randomized controlled trials in recent years. The aim of this article is to summarize current indications for the use of plasmapheresis in immunologic renal disease.

show abstract

World apheresis registry 2003–2007 data

Cited by 69 publications

References 24 publications

Spectra Optia apheresis system: experience with secondary plasma devices

Spectra Optia apheresis system: experience with secondary plasma devices

Theraputic Plasmapheresis in Neurological Disorders, Baghdad/Iraq

Plasmapheresis in Immunologic Renal Disease

Contact Info

Product

Resources

About